NCT00577837 - Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD | Biotech Hunter

Enrollment

370

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions

Postmenopausal

Interventions

DRUG

risedronate

tablet, 5 mg risedronate daily for 6 months

DRUG

risedronate

tablet, 100 mg risedronate monthly for 6 months

DRUG

risedronate

tablet, 150 mg risedronate monthly for 6 months

DRUG

experimental

tablet, 200 mg risedronate monthly for 6 months

Trial Locations (14)

Research Site, Daytona Beach

Research Site, Gainesville

Research Site, Shawnee Mission

Research Site, San Antonio

Research Site, Hamilton

Research Facility, Montreal

Research Facility, Sainte-Foy

Research Facility, Zagreb

Research Facility, Amsterdam

Research Facility, Leiden

Research Facility, Bialystok

Research Site, Lublin

Research Site, Warsaw

Research Site, Wroclaw